Showing results (41-50 of 1,282) with videos related to
Sort By:
Pageof 129
Atherosclerosis. Supplements|July 24, 2012
Statins are diabetogenic--myth or reality?Naveed Sattar, Marja-Riitta TaskinenCurrent Cardiology Reports|November 20, 2016
Glycaemic Effects of Non-statin Lipid-Lowering TherapiesPatrick D Collins, Naveed SattarNature Reviews. Cardiology|May 16, 2023
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and preventionNathan D Wong, Naveed SattarJournal of Clinical Medicine|June 28, 2023
Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?Andrew D Schreiner, Naveed SattarThe American Journal of Cardiology|August 29, 2017
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes MellitusNaveed Sattar, Peter P Toth, Dirk J Blom, et al.Circulation|March 7, 2022
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular DiseaseCiaran N Kohli-Lynch, James Lewsey, Kathleen A Boyd, et al.Alcohol and Alcoholism (Oxford, Oxfordshire)|September 7, 2021
The Role of Micronutrients in the Pathogenesis of Alcohol-Related Liver DiseaseRuairidh Nicoll, Konstantinos Gerasimidis, Ewan ForrestHypertension (Dallas, Tex. : 1979)|December 16, 2015
Prediction of Cardiovascular Disease Risk by Cardiac Biomarkers in 2 United Kingdom Cohort Studies: Does Utility Depend on Risk Thresholds For Treatment?Paul Welsh, Carole Hart, Olia Papacosta, et al.The Lancet. Diabetes & Endocrinology|August 19, 2019
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren L Kristensen, Rasmus Rørth, Pardeep S Jhund, et al.Diabetes, Obesity & Metabolism|April 11, 2023
A review of current key guidelines for managing high-risk patients with diabetes and heart failure and future prospectsMatthew M Y Lee, Naveed SattarPageof 129